Table 1.
Demographic and clinical information on disease and control groups.
| Cohort | SSc 1 | SSc 2 | HC 1 | HC 2 |
|---|---|---|---|---|
| Patients (#) | 81 | 20 | 40 | 24 |
| Specimen | Plasma | Plasma | Plasma | Plasma |
| Age in years (Median, range) | 47 (20-80) | 67 (19-82) | 57 (26-71) | 35 (18-67) |
| Disease duration (Median, range) | 4.5 (0-29) | 8.5 (0-19) | N/A | N/A |
| Gender (% female) | 100 | 80 | 85 | 88 |
| Ethnicity (White, %) | 72 | 95 | 100 | 96 |
| lcSSc (%) | 31 | 60 | N/A | N/A |
| dcSSc (%) | 65 | 40 | N/A | N/A |
| ACA+ (%) | 23 | 25 | N/A | N/A |
| Scl70 (%) | 20 | 25 | N/A | N/A |
| RNAPIII (%) | 28 | 15 | N/A | N/A |
| SMN1 (%) | 3 | N/D | N/A | N/A |
| p53 (%) | 4 | N/D | N/A | N/A |
| Ro52 (%) | 16 | N/D | N/A | N/A |
| PM-Scl-75 | 9 | N/D | N/A | N/A |
| PM-Scl-100 | 8 | N/D | N/A | N/A |
| Th/To | 13 | N/D | N/A | N/A |
| U11/12 RNPC3 | 16 | N/D | N/A | N/A |
| Skin score | ND | 4 (0-43) | N/A | N/A |
| Telangiectasia (%) | ND | 40 | N/A | N/A |
| Digital pitting scar (%) | ND | 45 | N/A | N/A |
| NT-pro-BNP | ND | 226 (0-1342) | N/A | N/A |
lcSSc, Limited cutaneous scleroderma; dcSSc, Diffuse cutaneous scleroderma. No data on lcSSc or dcSSc manifestation in 4% SSc patients from (Cohort I). ACA: Anti-centromere Abs. Scl70: Anti-topoisomerase Abs.
RNAPIII: Anti-RNA Polymerase III. SMN1, Anti-survival of motor neuron 1; U11/12 (RNPC3), Anti-Ribonucleoprotein.